$GLSI
Greenwich LifeSciences, Inc.

2023 Q2 Form 10-Q Financial Statement

#000149315223018539 Filed on May 22, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $368.3K $413.2K $328.4K
YoY Change 162.93% 25.82% 2.62%
% of Gross Profit
Research & Development $1.380M $1.828M $1.661M
YoY Change 117.86% 10.06% 493.15%
% of Gross Profit
Depreciation & Amortization $910.00 $900.00 $900.00
YoY Change 0.0% 0.0%
% of Gross Profit
Operating Expenses $1.748M $2.241M $1.989M
YoY Change 126.02% 12.66% 231.53%
Operating Profit -$1.748M -$2.241M -$1.989M
YoY Change 126.02% 12.66%
Interest Expense $119.5K $116.2K $19.58K
YoY Change 338.67% 493.36%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$1.628M -$2.125M -$1.970M
YoY Change 118.26% 7.88% 228.27%
Income Tax
% Of Pretax Income
Net Earnings -$1.628M -$2.125M -$1.970M
YoY Change 118.26% 7.88% 229.92%
Net Earnings / Revenue
Basic Earnings Per Share -$0.13 -$0.17 -$0.15
Diluted Earnings Per Share -$0.13 -$0.17 -$150.8K
COMMON SHARES
Basic Shares Outstanding 12.85M shares 12.85M shares
Diluted Shares Outstanding 12.85M shares 12.85M shares

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $10.94M $11.91M $19.74M
YoY Change -36.33% -39.67% -35.06%
Cash & Equivalents $10.94M $11.91M $19.74M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $10.94M $11.91M $19.74M
YoY Change -36.33% -39.67% -35.06%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $7.199K $8.099K $11.71K
YoY Change -33.4% -30.84% -41.45%
TOTAL ASSETS
Total Short-Term Assets $10.94M $11.91M $19.74M
Total Long-Term Assets $7.199K $8.099K $11.71K
Total Assets $10.95M $11.92M $19.75M
YoY Change -36.32% -39.66% -35.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $300.5K $220.9K $220.9K
YoY Change 36.05% 0.0% -63.8%
Accrued Expenses $1.080K $14.73K $20.32K
YoY Change -86.97% -27.51% -66.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $301.5K $235.6K $241.2K
YoY Change 31.6% -2.32% -64.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $301.5K $235.6K $241.2K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $301.5K $235.6K $241.2K
YoY Change 31.6% -2.32% -64.0%
SHAREHOLDERS EQUITY
Retained Earnings -$45.23M -$43.60M
YoY Change 24.37%
Common Stock $55.88M $55.28M
YoY Change 4.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $10.65M $11.68M $19.51M
YoY Change
Total Liabilities & Shareholders Equity $10.95M $11.92M $19.75M
YoY Change -36.32% -39.66% -35.06%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$1.628M -$2.125M -$1.970M
YoY Change 118.26% 7.88% 229.92%
Depreciation, Depletion And Amortization $910.00 $900.00 $900.00
YoY Change 0.0% 0.0%
Cash From Operating Activities -$967.0K -$1.557M -$1.947M
YoY Change 81.52% -20.06% 267.45%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 -5.514M
YoY Change -100.0% -342.89%
NET CHANGE
Cash From Operating Activities -967.0K -$1.557M -1.947M
Cash From Investing Activities
Cash From Financing Activities 0.000 -5.514M
Net Change In Cash -967.0K -$1.557M -7.461M
YoY Change -62.16% -79.13% -528.8%
FREE CASH FLOW
Cash From Operating Activities -$967.0K -$1.557M -$1.947M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001799788
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
usd
CY2023Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2022Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
usd
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-39555
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
GREENWICH LIFESCIENCES, INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-5473709
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3992 Bluebonnet Dr.
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building 14
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Stafford
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77477
CY2023Q1 dei City Area Code
CityAreaCode
832
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
819-3232
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock
CY2023Q1 dei Trading Symbol
TradingSymbol
GLSI
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12848165 shares
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11911219 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13468026 usd
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
8100 usd
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
9003 usd
CY2023Q1 us-gaap Assets
Assets
11919319 usd
CY2022Q4 us-gaap Assets
Assets
13477029 usd
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
14730 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
42060 usd
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
235575 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
262905 usd
CY2023Q1 us-gaap Liabilities
Liabilities
235575 usd
CY2022Q4 us-gaap Liabilities
Liabilities
262905 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12848165 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12848165 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
12848 usd
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55268564 usd
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54674042 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-43597668 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-41472766 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11683744 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
11919319 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13477029 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1827907 usd
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1660821 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
413175 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
328382 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
2241082 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
1989203 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2241082 usd
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1989203 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
116180 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
19575 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1969628 usd
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13063710 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
26831712 usd
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
165267 usd
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
5513711 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1969628 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
19513640 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
13214124 usd
CY2023Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
594522 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11683744 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
11683744 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2124902 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-1969628 usd
CY2023Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
903 usd
CY2022Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
903 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
594522 usd
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
165267 usd
CY2023Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-27330 usd
CY2022Q1 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-144004 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1556807 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1947462 usd
CY2022Q1 us-gaap Repayments Of Related Party Debt
RepaymentsOfRelatedPartyDebt
5513711 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5513711 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1556807 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7461173 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
13468026 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
27204269 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11911219 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19743096 usd
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
2555 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2124902 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1969628 usd
CY2023Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2124902 usd
CY2022Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1969628 usd
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
12848165 shares
CY2022Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
13063710 shares
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2023Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2022Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
220845 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
893181 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
908362 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
120 shares
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2009657 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
15181 shares
CY2023Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
34157 usd
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
0 shares
CY2023Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
519828 shares
CY2023Q1 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
7536216 usd
CY2023Q1 us-gaap Stock Repurchased And Retired During Period Shares
StockRepurchasedAndRetiredDuringPeriodShares
0 shares
CY2022Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
269828 shares
CY2022Q1 us-gaap Stock Repurchase Program Remaining Authorized Repurchase Amount1
StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
5513711 usd
CY2023Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
133199 usd
CY2023Q1 GLSI Closing Share Price
ClosingSharePrice
13.79
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
20174 shares

Files In Submission

Name View Source Status
0001493152-23-018539-index-headers.html Edgar Link pending
0001493152-23-018539-index.html Edgar Link pending
0001493152-23-018539.txt Edgar Link pending
0001493152-23-018539-xbrl.zip Edgar Link pending
ex31-1.htm Edgar Link pending
ex32-1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
glsi-20230331.xsd Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
glsi-20230331_cal.xml Edgar Link unprocessable
glsi-20230331_def.xml Edgar Link unprocessable
glsi-20230331_lab.xml Edgar Link unprocessable
glsi-20230331_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed